Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERNAN A SALAZAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538220892
CMS profile
919244
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$727.75

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $504.53 3
Food and Beverage $223.22 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $727.75 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERNAN A SALAZAR

NPI 1538220892 · CMS profile ID 919244

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538220892?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538220892?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538220892?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1538220892?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $727.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NOVARTIS PHARMACEUTICALS CORPORATION $223.2203/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423825 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $442.5403/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423827 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $21.9903/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423829 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $40.0003/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423831 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $713.29 23
PY2020 $397.53 3
PY2023 $727.75 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,942.29 38
PY2024 Principal investigator $116,310.00 16
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,683,804.34 55
PY2022 Recipient $1,491.00 2
PY2022 Principal investigator $4,307,067.33 117
PY2021 Recipient $201.98 1
PY2021 Principal investigator $8,685,200.41 155
PY2020 Recipient $145.50 1
PY2020 Principal investigator $2,390,117.44 47
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,142,050.05 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Endo Pharmaceuticals Inc. $8,649.00 12/14/2022 Non-covered Recipient Entity
CLINICAL PHARMACOLOGY OF MIAMI LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188155
Principal investigator 1 Janssen Research & Development, LLC $2,420.00 11/18/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214427
Principal investigator 1 Heron Therapeutics, Inc. $80,162.15 11/17/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265475
Principal investigator 1 Janssen Research & Development, LLC $108,297.00 11/02/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,320.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $85.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,610.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $76.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $74.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $365.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $650.00 10/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086371
Principal investigator 1 Janssen Research & Development, LLC $138,663.00 10/21/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214435
Principal investigator 1 Janssen Research & Development, LLC $87,668.00 10/19/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214439
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,196.56 10/19/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy No dispute reported 06/30/2026 904834251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,149.84 10/05/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937175345
Principal investigator 1 PFIZER INC. $4,761.96 09/28/2022 Non-covered Recipient Entity
ERG Holding Company LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949785033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,600.00 09/21/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937174743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 09/07/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937173417
Principal investigator 1 Heron Therapeutics, Inc. $71.50 09/01/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,251.00 08/24/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086151
Principal investigator 1 Endo Pharmaceuticals Inc. $10,151.00 08/24/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188229
Principal investigator 1 Janssen Research & Development, LLC $6,479.00 08/19/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214407
Principal investigator 1 Janssen Research & Development, LLC $38,139.50 08/11/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Study for the identification of subjects who are homozygous for the PNPLA3 I148M mutation and have Nonalcoholic fatty liver disease (NAFLD) No dispute reported 06/30/2026 885255717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $65,950.20 08/03/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937172291
Principal investigator 1 Endo Pharmaceuticals Inc. $5,256.00 08/02/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,116.00 07/25/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086141
Principal investigator 1 Janssen Research & Development, LLC $50,959.00 07/22/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214403
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,759.92 07/13/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED CARDIOVASCULAR DISEASE (VICTORION-2 PREVENT) No dispute reported 06/30/2026 909399503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,103.65 07/13/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937171441
Principal investigator 1 Endo Pharmaceuticals Inc. $5,743.00 07/12/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188211
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $533,560.09 07/06/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of VX-121/Tezacaftor/Deutivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects No dispute reported 06/30/2026 904833557
Principal investigator 1 Janssen Research & Development, LLC $14,875.00 07/05/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214399
Principal investigator 1 PFIZER INC. $4,250.00 07/01/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949784499
Principal investigator 1 Genentech, Inc. $23,491.00 06/23/2022 Non-covered Recipient Entity
NEW ORLEANS CENTER FOR
PH1A SAD STUDY OF RO7303509 IN HEALTHY VOLUNTEERS LOOKING AT SAFETY PK No dispute reported 06/30/2026 950728947
Principal investigator 1 Janssen Research & Development, LLC $34,174.00 06/17/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214340
Principal investigator 1 Janssen Research & Development, LLC $34,174.00 06/17/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,841.60 06/15/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A FIRST-IN-HUMAN, TWO-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925 IN HEALTHY ADULT AND ELDERLY VOLUNTEERS AND PATIENTS WITH NARCOLEPSY No dispute reported 06/30/2026 937170131
Principal investigator 1 Innocoll Pharmaceuticals Limited $500.00 06/13/2022 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110111
Principal investigator 1 Heron Therapeutics, Inc. $2,706.30 05/26/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265433
Principal investigator 1 Janssen Research & Development, LLC $22,128.00 05/20/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214335
Principal investigator 1 Janssen Research & Development, LLC $22,128.00 05/20/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,070.00 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,672.90 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,176.60 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,381.45 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168501
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,669.50 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $61,999.40 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168505
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $188,504.00 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $335,119.00 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,569.38 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,706.00 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,226.88 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,704.08 05/18/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937168517
Principal investigator 1 Heron Therapeutics, Inc. $35,079.75 05/12/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265417
Principal investigator 1 Janssen Research & Development, LLC $6,479.00 05/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214331
Principal investigator 1 Janssen Research & Development, LLC $6,479.00 05/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214371
Recipient Eli Lilly and Company $1,200.00 04/29/2022 Covered Recipient Physician A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 917807009
Recipient Eli Lilly and Company $291.00 04/29/2022 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 917810089
Principal investigator 1 Dexcom, Inc. $26,211.00 04/26/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,616.00 04/22/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910086074
Principal investigator 1 Janssen Research & Development, LLC $63,436.00 04/22/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214327
Principal investigator 1 Janssen Research & Development, LLC $63,436.00 04/22/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214367
Principal investigator 1 Dexcom, Inc. $1,525.00 04/19/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) No dispute reported 06/30/2026 955569999
Principal investigator 1 Heron Therapeutics, Inc. $167,271.30 04/15/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265401
Principal investigator 1 Endo Pharmaceuticals Inc. $8,119.00 04/12/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188203
Principal investigator 1 Janssen Research & Development, LLC $11,318.00 04/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214325
Principal investigator 1 Janssen Research & Development, LLC $11,318.00 04/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214363
Principal investigator 1 Heron Therapeutics, Inc. $382,899.47 04/01/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265387
Principal investigator 1 Innocoll Pharmaceuticals Limited $1,500.00 04/01/2022 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty No dispute reported 06/30/2026 957110093
Principal investigator 1 Innocoll Pharmaceuticals Limited $500.00 04/01/2022 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110105
Principal investigator 1 Dexcom, Inc. $1,800.00 03/28/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569993
Principal investigator 1 Janssen Research & Development, LLC $28,112.00 03/28/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214277
Principal investigator 1 Janssen Research & Development, LLC $233,738.00 03/23/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214273
Principal investigator 1 Endo Pharmaceuticals Inc. $7,593.00 03/15/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17,035.00 03/11/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,012.00 03/11/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085961
Principal investigator 1 Janssen Research & Development, LLC $4,244.00 03/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 03/02/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937164205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,650.00 03/02/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 937164207
Principal investigator 1 Eli Lilly and Company $58,434.00 03/01/2022 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 917825467
Principal investigator 1 Endo Pharmaceuticals Inc. $1,314.00 03/01/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188185
Principal investigator 1 Heron Therapeutics, Inc. $1,573.00 02/24/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $116.00 02/23/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085895
Principal investigator 1 Janssen Research & Development, LLC $86,814.00 02/23/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214265
Principal investigator 1 Dexcom, Inc. $20,200.00 02/15/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569987
Principal investigator 1 Heron Therapeutics, Inc. $100.00 02/11/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265365
Principal investigator 1 Dexcom, Inc. $1,525.00 02/08/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 955569991
Principal investigator 1 PFIZER INC. $79.00 02/07/2022 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949784583
Principal investigator 1 Janssen Research & Development, LLC $29,656.00 02/04/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214261
Principal investigator 1 Vertex Pharmaceuticals Incorporated $296,817.99 02/04/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 2 Randomized Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty No dispute reported 06/30/2026 904835585
Principal investigator 1 Innocoll Pharmaceuticals Limited $5,200.00 02/01/2022 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
Efficacy and Safety Study of Postsurgical Analgesia With INL-001 in Abdominoplasty No dispute reported 06/30/2026 957110089
Principal investigator 1 Innocoll Pharmaceuticals Limited $1,000.00 02/01/2022 Non-covered Recipient Entity
Endeavor Clinical Trials LLC
An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries No dispute reported 06/30/2026 957110099
Principal investigator 1 Eli Lilly and Company $856.00 01/31/2022 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 917820351
Principal investigator 1 Heron Therapeutics, Inc. $168,602.54 01/27/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265361
Principal investigator 1 Eli Lilly and Company $90.00 01/26/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 917824967
Principal investigator 1 Eli Lilly and Company $5,046.00 01/26/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 917825525
Principal investigator 1 Janssen Research & Development, LLC $22,119.00 01/26/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214257
Principal investigator 1 AstraZeneca UK Limited $48,282.85 01/20/2022 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AZD2693, Cardiovascular, Renal and Metabolism No dispute reported 06/30/2026 914600915
Principal investigator 1 Dexcom, Inc. $12,500.00 01/19/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569983
Principal investigator 1 Dexcom, Inc. $56,297.00 01/19/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569995
Principal investigator 1 Dexcom, Inc. $2,150.00 01/19/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM GLUCOSE MONITORING (CGM) (G7 OUS) No dispute reported 06/30/2026 955569997
Principal investigator 1 Endo Pharmaceuticals Inc. $9,317.00 01/18/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188165
Principal investigator 1 Endo Pharmaceuticals Inc. $6,101.00 01/18/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 929188175
Principal investigator 1 PFIZER INC. $113.80 01/14/2022 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949784227
Principal investigator 1 PFIZER INC. $920.00 01/14/2022 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949784613
Principal investigator 1 Heron Therapeutics, Inc. $17,500.00 01/13/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 920265347
Principal investigator 1 Eli Lilly and Company $249,098.00 01/12/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 917822199
Principal investigator 1 Dexcom, Inc. $4,250.00 01/11/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 955569985
Principal investigator 1 Janssen Research & Development, LLC $288.00 01/07/2022 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 885214253
Principal investigator 1 Heron Therapeutics, Inc. $10,587.94 01/06/2022 Non-covered Recipient Entity
ERG Holding Company LLC
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen No dispute reported 06/30/2026 920265341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $76.00 01/05/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $365.00 01/05/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,150.00 01/05/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21.00 01/05/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 01/05/2022 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 910085763
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,832.23 01/01/2022 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO No dispute reported 06/30/2026 909399493